41 related articles for article (PubMed ID: 3930444)
1. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase.
Uehara Y; Hori M; Takeuchi T; Umezawa H
Jpn J Cancer Res; 1985 Aug; 76(8):672-5. PubMed ID: 3930444
[TBL] [Abstract][Full Text] [Related]
2. Stress biology: Complexity and multifariousness in health and disease.
Mayer MP; Blair L; Blatch GL; Borges TJ; Chadli A; Chiosis G; de Thonel A; Dinkova-Kostova A; Ecroyd H; Edkins AL; Eguchi T; Fleshner M; Foley KP; Fragkostefanakis S; Gestwicki J; Goloubinoff P; Heritz JA; Heske CM; Hibshman JD; Joutsen J; Li W; Lynes M; Mendillo ML; Mivechi N; Mokoena F; Okusha Y; Prahlad V; Repasky E; Sannino S; Scalia F; Shalgi R; Sistonen L; Sontag E; van Oosten-Hawle P; Vihervaara A; Wickramaratne A; Wang SXY; Zininga T
Cell Stress Chaperones; 2024 Feb; 29(1):143-157. PubMed ID: 38311120
[TBL] [Abstract][Full Text] [Related]
3. Approach toward molecular targeted therapy for cancer using microbial products.
Imoto M
J Antibiot (Tokyo); 2021 Oct; 74(10):601-602. PubMed ID: 34565796
[No Abstract] [Full Text] [Related]
4. Professor Hamao Umezawa opened up a new road for the development of molecularly targeted therapeutic drugs for cancers.
Imoto M
J Antibiot (Tokyo); 2017 Nov; ():. PubMed ID: 29089596
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screen of natural product libraries for hsp90 inhibitors.
Davenport J; Balch M; Galam L; Girgis A; Hall J; Blagg BS; Matts RL
Biology (Basel); 2014 Feb; 3(1):101-38. PubMed ID: 24833337
[TBL] [Abstract][Full Text] [Related]
6. Efficient Synthesis of a Novel Resorcyclide as Anticancer Agent Based on Hsp90 Inhibition.
Lei X; Danishefsky SJ
Adv Synth Catal; 2008 Aug; 350(11-12):1677-1681. PubMed ID: 21442009
[TBL] [Abstract][Full Text] [Related]
7. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage.
Pratt WB; Morishima Y; Peng HM; Osawa Y
Exp Biol Med (Maywood); 2010 Mar; 235(3):278-89. PubMed ID: 20404045
[TBL] [Abstract][Full Text] [Related]
8. New drugs in gynecologic cancer.
Daud A; Munster P; Munster P; Spriggs DR
Curr Treat Options Oncol; 2001 Apr; 2(2):119-28. PubMed ID: 12057130
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
Ochel HJ; Eichhorn K; Gademann G
Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
[No Abstract] [Full Text] [Related]
10. A balance between positive and negative signals in cytotoxic lymphocytes regulates the polarization of lipid rafts during the development of cell-mediated killing.
Lou Z; Jevremovic D; Billadeau DD; Leibson PJ
J Exp Med; 2000 Jan; 191(2):347-54. PubMed ID: 10637278
[TBL] [Abstract][Full Text] [Related]
11. Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation.
Suttitanamongkol S; Gear AR; Polanowska-Grabowska R
Biochem J; 2000 Jan; 345 Pt 2(Pt 2):307-14. PubMed ID: 10620508
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line.
Mancini M; Anderson BO; Caldwell E; Sedghinasab M; Paty PB; Hockenbery DM
J Cell Biol; 1997 Jul; 138(2):449-69. PubMed ID: 9230085
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90.
Schneider C; Sepp-Lorenzino L; Nimmesgern E; Ouerfelli O; Danishefsky S; Rosen N; Hartl FU
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14536-41. PubMed ID: 8962087
[TBL] [Abstract][Full Text] [Related]
14. Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells.
McIlwrath AJ; Brunton VG; Brown R
Cancer Chemother Pharmacol; 1996; 37(5):423-8. PubMed ID: 8599864
[TBL] [Abstract][Full Text] [Related]
15. ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice.
Arakawa H; Iguchi T; Yoshinari T; Kojiri K; Suda H; Okura A
Jpn J Cancer Res; 1993 May; 84(5):574-81. PubMed ID: 8320174
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells.
Romer LH; McLean N; Turner CE; Burridge K
Mol Biol Cell; 1994 Mar; 5(3):349-61. PubMed ID: 8049526
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the requirement of protein synthesis and protein kinase activity in the temperature regulated stability of a Tetrahymena surface protein mRNA.
McMillan PJ; Stanley JS; Bannon GA
Nucleic Acids Res; 1995 Mar; 23(6):942-8. PubMed ID: 7731807
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of erythroid progenitor (CFU-E) cells from mouse fetal liver cells and murine erythroleukemia (TSA8) cells without proliferation.
Noguchi T; Fukumoto H; Mishina Y; Obinata M
Mol Cell Biol; 1988 Jun; 8(6):2604-9. PubMed ID: 3165492
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of fibronectin expression by herbimycin A.
Umezawa K; Atsumi S; Matsushima T; Takeuchi T
Experientia; 1987 Jun; 43(6):614-6. PubMed ID: 3036558
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus.
Uehara Y; Hori M; Takeuchi T; Umezawa H
Mol Cell Biol; 1986 Jun; 6(6):2198-206. PubMed ID: 3023921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
